EP0977988A1 - Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene - Google Patents

Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene

Info

Publication number
EP0977988A1
EP0977988A1 EP98920866A EP98920866A EP0977988A1 EP 0977988 A1 EP0977988 A1 EP 0977988A1 EP 98920866 A EP98920866 A EP 98920866A EP 98920866 A EP98920866 A EP 98920866A EP 0977988 A1 EP0977988 A1 EP 0977988A1
Authority
EP
European Patent Office
Prior art keywords
optical signal
extracellular protein
cells
operably linked
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98920866A
Other languages
German (de)
English (en)
Other versions
EP0977988A4 (fr
Inventor
Damien J. Dunnington
Keith J. Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of EP0977988A1 publication Critical patent/EP0977988A1/fr
Publication of EP0977988A4 publication Critical patent/EP0977988A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Definitions

  • the present invention relates to an improved fluorescence reporter assay system and its use in screening compounds and combinatorial libraries.
  • BACKGROUND OF THE INVENTION Screening of compounds for pharmacological activity is dependent on a means of measuring the effect of the compounds on a pharmacologically relevant process, such as activation or inhibition of specific gene expression.
  • a pharmacologically relevant process such as activation or inhibition of specific gene expression.
  • this may be done by engineering a DNA construct containing the promoter region of the gene of interest coupled to a readily detectable 'reporter' gene, such as an enzyme or fluorescent protein.
  • the construct is transfected into a recipient cell and the effect of compounds on expression of the reporter gene is measured by assaying the level of enzyme or fluorescent protein produced by the cell.
  • reporter genes include chloramphenicol acetyltransferase (CAT), firefly luciferase, beta galactosidase (beta-gal), secreted alkaline phosphatase or green fluorescent protein (GFP).
  • CAT chloramphenicol acetyltransferase
  • beta-gal beta galactosidase
  • GFP green fluorescent protein
  • CAT beta-gal and luciferase all require cell lysis which precludes their use as selectable markers, making selection of stably transfected cell lines a time consuming process dependent on co-expressed antibiotic resistance markers. Additionally, CAT assays require either chromatographic detection of reaction product or indirect antibody detection which is inconvenient for high throughput screening, while luciferase has a limited duration of signal generation, which in turn limits the time for signal measurement. GFP has sensitivity limitations due to the presence of only one fluorophore per GFP molecule and therefore requires large numbers of cells.
  • the GFP molecule is also extremely stable, making it unsuitable for monitoring decreases in gene expression. GFP is also unsuitable for srceening compounds that fluoresce or absorb strongly within its absorption or emission wavelength.
  • the latter problem also applies to beta lactamase readouts, while secreted alkaline phosphatase suffers from high backgrounds due to endogenous alkaline phosphatase activity. Multiplexing (allowing for the measurement of expression of more than one gene per cell) is difficult with all of the above readouts.
  • This invention relates to a fluorescence reporter assay system.
  • This invention also relates to a homogeneous fluorescence reporter assay system.
  • This invention also relates to a time resolved fluorescence reporter assay system.
  • This invention also relates to a reporter assay system that is compatible with miniaturized assay formats.
  • This invention also relates to a method of conducting high throughput screening using the presently invented fluorescence reporter assay system.
  • This invention also relates to a method of screening combinatorial libraries using the presently invented fluorescence reporter assay system.
  • This invention also relates to compounds identified by the presently invented fluorescence reporter assay system and presently invented methods.
  • This invention relates to an improved fluorescence reporter screening system that allows for gene expression in intact cells, has no washing steps that might impede use of the assay in nanowell format, has no endogenous activity in untransfected cells, allows measurement of expression of more than one gene per cell (multiplexing), has a high signal to noise ratio and a long readout duration.
  • the presently invented fluorescence reporter assay system uses an extracellular marker capable of generating an optical readout. It can be detected and quantitated without lysing the cells, is unaffected by compound fluorescence, allows multiplexing, requires no washing steps, has no endogenous background in mammalian cells and has a low background and long duration of appearance.
  • the presently invented fluorescence reporter assay system comprises a nucleotide sequence encoding a promoter/enhancer region, an extracellular protein (defined herein as either a cell surface or secreted protein) containing sequences coding for one or more binding partners or other molecules capable of generating an optical signal; a recipient cell; accessory molecules necessary to produce and/or enhance the optical signal and an optical detection apparatus.
  • the extracellular protein is xenogeneic (defined herein as a protein that is not naturally produced by the recipient cell type).
  • the nucleic acid construct is prepared such that expression of the cell surface or secreted protein is driven by the promoter/enhancer region, the latter being derived from a pharmacologically relevant protein target.
  • pro-alpha 1 chain of Type 1 collagen which is specifically expressed in osteoblasts and is linked to formation of new bone matrix (Identification of a minimal sequence of the mouse pro-alpha 1 (I) collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Rossert-JA; Chen-SS; Eberspaecher-H; Smith-CN; de-Crombrugghe-B Proc- Natl-Acad-Sci-USA. 1996; 93(3): 1027-31).
  • the extracellular protein is constructed with the optical signal-generating sequences inserted in frame within or appended to the coding sequence and carries additional sequences specifying membrane targeting or secretion (Duffaud GD et al, in: Current Topics in Membranes and Transport, Chapter 2 Vol. 24, Academic Press NY, 1985).
  • the optical signal may be generated directly, for example, by inserting sequences encoding for firefly luciferase.
  • the optical signal may be generated indirectly, for example, by providing binding sites for exogenous binding partners that contain optically active constituents such as fluorescent dyes or enzymes capable of generating optically detectable products.
  • polypeptide sequences that are not naturally present on or produced by the recipient cell are preferred to minimize background.
  • An example of a suitable extracellular protein with an indirect optical readout is the epidermal growth factor (EGF) receptor, with two or more defined epitope tags inserted into the extracellular domain.
  • EGF epidermal growth factor
  • a defined epitope tag is preferably a short non-mammalian polypeptide sequence that is recognized by a specific monoclonal antibody, such as the 11 amino acid epitope from Human Immunodeficiency Virus Type 1 (HIV-1) envelope protein gpl20 (or gpl60) that is recognized by the monoclonal antibody 178.1 (see, e.g., Thiriart et al., J. Immunol., 143: 1832-1836 (1989)), which was prepared by immunization of mice with a yeast-expressed HIV-1 gp 160 molecule from strain BH10 (Ratner et al., Nature. 313: 277-284 (1985)).
  • a specific monoclonal antibody such as the 11 amino acid epitope from Human Immunodeficiency Virus Type 1 (HIV-1) envelope protein gpl20 (or gpl60) that is recognized by the monoclonal antibody 178.1 (see, e.g., Thiriart
  • DET is the commercially available FLAG tagging system from Eastman Kodak, Rochester NY.
  • each molecule of the EGF receptor carries tandem copies of each of two DETs and the copies may be repeated within the molecule to afford additional binding sites.
  • the DET sequences may be inserted into a secreted protein such as human growth hormone. It will be appreciated that there are many variations for implementation of such an extracellular protein. All such variations are included within the scope of this invention.
  • the minimal essential features of the construct are a promoter/enhancer region, a membrane or secretion-targeting signal sequence(s), a transmembrane or membrane insertion region for cell surface proteins and a polypeptide that is directly or indirectly capable of generating an optically readable signal.
  • An additional, preferred, component of this invention is the provision of accessory molecules for generation and or enhancement of the optical signal.
  • Such molecules include but are not limited to antibodies labeled with fluorescent dyes, substrates for light-generating enzymes or color-generating reagents for enzymes.
  • two exogenous binding partners are provided, each of which recognizes one of the DET sequences that was inserted into the extracellular domain of the extracellular protein.
  • one or both exogenous binding partners may recognize spatially discrete regions of a naturally occurring extracellular protein used in the above promoter/enhancer construct and which is not present on or produced by the chosen recipient cell, such that when bound, the two exogenous binding partners are separated by a distance comparable to or less than the energy transfer radius for the chosen fluorophores.
  • exogenous binding partners are monoclonal antibodies to DETs. These binding partners are each labelled, preferably with fluorescent dyes capable of resonance energy transfer. Preferably, one of the dyes is capable of time resolved fluorescence (luminescence). Examples of such dyes are terbium chelate/cryptates (Selvin P R and Hearst (J E. Proc. Natl. Acad. Sci. 91: 10024- 10028, 1994) and tetramethyl rhodamine (Molecular Probes, Eugene, OR). Methods for labelling antibodies with fluorescent dyes are well known in the art.
  • An additionally preferred component of this invention is a recipient cell.
  • This cell may be of eukaryotic or prokaryotic origin and in the former case may be somatic or germline.
  • the preferred cell type is mammalian, preferably a human cell line that can be maintained in culture.
  • An example of such a cell line is the human embryonic kidney cell line HEK293 which is available from the American Type Culture Collection. Methods for transfection of mammalian cells with nucleic acid constructs are well known to one skilled in the art. Depending on the nature of the promoter, it may be necessary to stimulate the cells with a hormone or other substance to initiate expresion of the extracellular protein.
  • An additionally preferred component of this invention is a device capable of detecting and measuring the optical signal.
  • a device should produce a numeric or graphical output that is related to the intensity and wavelength of the optical signal. It should be sensitive to the wavelength of the optical signal and may contain a source of electromagnetic radiation to assist in the generation of the optical signal, for example, an excitation source for fluorophores. It may also incorporate a time delay mechanism such that excitation radiation may be applied for a discrete time interval and measurement may be initiated at a specific time after termination of the excitation. Examples of such devices are fluorimeters, fluorescence correlation spectrometers, luminometers, spectrophotometers, CCD cameras, photon counters and fluorescence activated cell sorters. Such devices are readily available from commercial sources.
  • the polynucleotide construct is transfected into the chosen recipient cell. If the promoter is active in the cellular environment, it drives expression of the extracellular protein, which leads to display on the cell surface or secretion of the protein carrying the tandem binding partners. Cells that express high levels of a construct utilizing a cell surface protein are selected by addition of the labelled exogenous binding partners, followed by fluorescence activated cell sorting. Cells that produce secreted markers are cloned by limiting dilution and selected by monitoring of the culture media for the optical signal.
  • accessory molecules are added to the culture media.
  • monoclonal anti-DET antibodies labeled with fluorescent dyes that are capable of resonance energy transfer are added.
  • the fluorescent dyes Upon binding to their respective recognition sites on the extracellular protein, the fluorescent dyes are brought within their critical radii for resonance energy transfer and emission from the donor or acceptor dye is used to select cells that express high levels of the extracellular protein. These cells may be subjected to iterative selections as above to generate stable transfectants.
  • the optical signal is detected by using a suitable detection device as above.
  • the cells are used for screening compound collections or combinatorial libraries.
  • Cells are plated in test wells in groups, preferably of more than 100 cells, to average out cell-to cell variations in reporter expression levels.
  • Test compounds are added with or without an inducing hormone or other substance as appropriate for the promoter region of interest.
  • accessory reagents are added to each well.
  • the optical signal is quantitated using a suitable detection device.
  • cells are co-transfected with two or more constructs of the same extracellular protein but with different promoter regions driving each construct. For each construct, the optical signal-generating sequences are chosen to give distinct signals.
  • peptide binding partners are chosen such that they interact with distinct exogenous binding partners.
  • cells may be transfected with promoter 1 linked to DET1-DET2 and with promoter 2 linked to DET1-DET3 or DET3-DET4.
  • the accessory molecules are each labelled with a fluorophore of distinct abso ⁇ tion or emission wavelength.
  • an antibody to DET1 could be labeled with terbium chelate/cryptate (emission 545 nm), anti-DET2 with TMR (excitation 550 nm emission 575 nm) and anti-DET3 with samarium chelate/cryptate (emission 655 nm) and DET4 with Cy5 (Amersham, Arlington Heights IL) (excitation 650nm emission 670nm).
  • Stable transfectants are selected as above for expression of both constructs. Screening of test compounds is done as above but fluorescence emission is monitored both at 575 nm and 670 nm, so that differential effects of compounds on one or other promoter activity can be measured.
  • the advantages of this process compared with existing reporter gene systems are 1) it allows the use of time resolving dyes which are insensitive to fluorescence of test compounds or cellular components, 2) it allows unrestricted choice of fluorophores for multiplexing and avoidance of quenching by test compounds, 3) it does not require cell lysis so the selection of stable transfectants is simplified, 4) the signal is present for a long duration so that time-dependent imaging can be used for detection 5) multiple fluorophores can be conjugated to each accessory molecule and multiple binding partner sequences can be added to the extracellular protein for increased sensitivity 6) no washing steps are needed which simplifies high throughput screening 7) the binding partners can be chosen from microbial, viral, fungal, insect or artificial sources so that no such molecules occur endogenously on mammalian cells 8) signal to noise ratios are enhanced by the requirement that two specific binding events must occur in close proximity to one another for signal generation, and by the use of time resolving dyes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

L'invention concerne un système de test par fluorescence de gène reporter qui ne nécessite aucune étape de lavage ou de lyse cellulaire, ce système pouvant effectuer une détection par fluorescence à résolution temporelle et étant approprié au multiplexage. L'invention concerne également un procédé permettant d'effectuer une détection à haut rendement à l'aide d'un système de test de gène reporter par fluorescence. L'invention concerne enfin un procédé de détection de bibliothèques combinatoires utilisé dans le système précité.
EP98920866A 1997-04-22 1998-04-22 Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene Withdrawn EP0977988A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4452797P 1997-04-22 1997-04-22
US44527P 1997-04-22
PCT/US1998/008101 WO1998048274A1 (fr) 1997-04-22 1998-04-22 Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene

Publications (2)

Publication Number Publication Date
EP0977988A1 true EP0977988A1 (fr) 2000-02-09
EP0977988A4 EP0977988A4 (fr) 2004-06-30

Family

ID=21932889

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98920866A Withdrawn EP0977988A4 (fr) 1997-04-22 1998-04-22 Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene

Country Status (4)

Country Link
EP (1) EP0977988A4 (fr)
JP (1) JP2002511744A (fr)
CA (1) CA2287427A1 (fr)
WO (1) WO1998048274A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418496A1 (fr) * 2000-02-24 2001-08-30 Incyte Genomics, Inc. Molecules secretoires
WO2001062927A2 (fr) * 2000-02-24 2001-08-30 Incyte Genomics Inc Molecules utilisees a des fins diagnostiques et therapeutiques
CA2401076A1 (fr) * 2000-02-24 2001-08-30 Incyte Genomics, Inc. Molecules destinees a la detection et au traitement de maladies
CA2421265A1 (fr) * 2000-09-05 2002-03-14 Incyte Genomics, Inc. Molecules utilisees a des fins diagnostiques et therapeutiques
US20080249103A1 (en) * 2006-11-15 2008-10-09 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327960A1 (fr) * 1988-02-11 1989-08-16 F. Hoffmann-La Roche Ag Formes sécrétables de phosphatase alcaline
US5156951A (en) * 1989-07-13 1992-10-20 Becton Dickinson And Company Detecting immunological changes in HIV infected patient samples
WO1995009240A1 (fr) * 1993-09-27 1995-04-06 University Of Massachusetts Medical Center Systemes de ligands actives par les recepteurs
EP0648841A2 (fr) * 1993-10-13 1995-04-19 Northeastern Ohio Universities ADN génomique du cholestérol-7-alpha hydroxylase et méthodes pour son utilisation
WO1996013610A2 (fr) * 1994-10-31 1996-05-09 Geron Corporation Procedes et reactifs servant a identifier et a reguler des genes relatifs a la senescence
EP0747700A2 (fr) * 1995-06-07 1996-12-11 Carnegie-Mellon University Complexe avec un grand décalage de stokes pour marquage fluorescent formé par couplage de cyanine et autres fluorochromes capables de transfert d'énergie résonance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7667191A (en) * 1990-04-19 1991-11-11 General Hospital Corporation, The Screening assays for compounds which inhibit the binding of c-myc to dna
GB9320562D0 (en) * 1993-10-06 1993-11-24 Zeneca Ltd Novel assay and applications
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
US5747338A (en) * 1996-08-15 1998-05-05 Chiron Corporation Method and construct for screening for inhibitors of transcriptional activation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327960A1 (fr) * 1988-02-11 1989-08-16 F. Hoffmann-La Roche Ag Formes sécrétables de phosphatase alcaline
US5156951A (en) * 1989-07-13 1992-10-20 Becton Dickinson And Company Detecting immunological changes in HIV infected patient samples
WO1995009240A1 (fr) * 1993-09-27 1995-04-06 University Of Massachusetts Medical Center Systemes de ligands actives par les recepteurs
EP0648841A2 (fr) * 1993-10-13 1995-04-19 Northeastern Ohio Universities ADN génomique du cholestérol-7-alpha hydroxylase et méthodes pour son utilisation
WO1996013610A2 (fr) * 1994-10-31 1996-05-09 Geron Corporation Procedes et reactifs servant a identifier et a reguler des genes relatifs a la senescence
EP0747700A2 (fr) * 1995-06-07 1996-12-11 Carnegie-Mellon University Complexe avec un grand décalage de stokes pour marquage fluorescent formé par couplage de cyanine et autres fluorochromes capables de transfert d'énergie résonance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRONSTEIN I ET AL: "CHEMILUMINESCENT AND BIOLUMINESCENT REPORTER GENE ASSAYS" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 219, no. 2, 1 June 1994 (1994-06-01), pages 169-181, XP000446239 ISSN: 0003-2697 *
KAETHER AND GERDES: "Visualization of protein transport along the secretory pathway using green fluorescent protein" FEBS LETTERS, vol. 369, 1995, pages 267-271, XP002275948 *
MITRA R D ET AL: "Fluorescence resonance energy transfer between blue-emitting and red-shifted excitation derivatives of the green fluorescent protein" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 173, no. 1, 1996, pages 13-17, XP004042847 ISSN: 0378-1119 *
See also references of WO9848274A1 *

Also Published As

Publication number Publication date
CA2287427A1 (fr) 1998-10-29
EP0977988A4 (fr) 2004-06-30
JP2002511744A (ja) 2002-04-16
WO1998048274A1 (fr) 1998-10-29

Similar Documents

Publication Publication Date Title
US6379884B2 (en) Methods and systems for monitoring intracellular binding reactions
Weibrecht et al. Proximity ligation assays: a recent addition to the proteomics toolbox
EP1567662B1 (fr) Capteurs, regulateurs et composes bloques et utilisations de ceux-ci
Giepmans Bridging fluorescence microscopy and electron microscopy
US6255048B1 (en) Highly sensitive fluoroassay
Shao et al. TagBiFC technique allows long-term single-molecule tracking of protein-protein interactions in living cells
CN107074926A (zh) 基于Gβγ互作蛋白监测G蛋白激活的生物传感器
US20040175765A1 (en) Cell-screening assay and composition
WO1998048274A1 (fr) Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene
US20050272035A1 (en) Functional screening method
EP1761647B1 (fr) Systeme a deux hybrides
WO2003006947A2 (fr) Methode et composition de criblage cellulaire
Douglass et al. Single‐Molecule Imaging of Fluorescent Proteins
US6472151B1 (en) Method of screening for compounds that modulate the activity of a molecular target
EP4092414A1 (fr) Connecteur, marqueur et procédé pour analyser des échantillons biologiques
Zlokarnik Peer Reviewed: Fluorescent Molecular Sensor for Drug Discovery.
US20080161199A1 (en) Fusion Proteins and Methods for Determining Protein-Protein-Interactions in Living Cells and Cell Lysates, Nucleic Acids Encoding these Fusion Proteins, as well as Vectors and Kits Containing These
US20240168031A1 (en) Connector, connector-label conjugate and marker for analysing biological samples
US20230258628A1 (en) Connector, marker and method for analysing biological samples
US20030022224A1 (en) Method of detecting binding reaction between protein and test substance
Sharma et al. 9.1 PROTEIN AS CRUCIAL BIOMOLECULES AND ITS LABELLING
Pawlak et al. RAD-TGTs: Measurement of cellular tensions via flow cytometry and DNA sequencing enabled by force-dependent rupture and delivery of DNA tension probes
US5910410A (en) Dual tag binding assay
US7541152B2 (en) Integrated light source for diagnostic arrays
CN116848266A (zh) 超灵敏生物传感器方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

17P Request for examination filed

Effective date: 19991012

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

Owner name: SMITHKLINE BEECHAM CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20040518

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040805